Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Antineoplastic Agents*/pharmacology ; Cell-Penetrating Peptides* ; Single-Chain Antibodies*/pharmacology; Cell Line, Tumor ; Gangliosides ; Humans ; Proto-Oncogene Proteins p21(ras)/immunology
    • نبذة مختصرة :
      Purpose: Cell membrane penetrating peptide BR2 can bind with ganglioside and introduce foreign drugs into tumor cells. In this study, we employed BR2 to carry the broad-spectrum anti-p21Ras scFv prepared in our laboratory into ganglioside expressing tumor cells for therapy of ras-driven tumors.
      Methods: BR2-p21Ras scFv gene was cloned to prokaryotic expression vector and expressed in E. coli BL21, then the fusion protein was purified with HisPur Ni-NTA. The immunoreactivity of the fusion protein with p21Ras was detected by ELISA and western blotting. The membrane-penetrating and immune co-localization with p21Ras of the fusion protein were determined by immunofluorescence. The antitumor activity was investigated using MTT, wound healing, colone formation, and apoptosis assays in vitro.
      Results: BR2-p21Ras scFv fusion protein was successfully expressed and purified. We found that the fusion protein could specifically penetrate into human tumor cell lines which express ganglioside including human neuroblastoma cell line SK-N-SH, human colon cancer cell line HCT116 and human glioma cell line U251. After entering tumor cells the fusion protein bonded specifically with p21Ras. In vitro experiments revealed that it could significantly inhibit the proliferation, migration, and colone formation of HCT116, SK-N-SH, and U251 cells and promote the apoptosis of these tumor cells.
      Conclusions: BR2-p21Ras scFv can penetrate ganglioside expressing tumor cells and inhibit the growth of ras-driven tumor by binding with p21Ras, and producing an inhibitory effect. It is suggested that BR2-p21Ras scFv is a potential ras-driven tumor therapeutic antibody.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      BMC Cancer. 2016 Feb 20;16:131. (PMID: 26897358)
      Oncotarget. 2017 Sep 16;8(56):95620-95631. (PMID: 29221154)
      Eur J Cancer Clin Oncol. 1986 Aug;22(8):1003-7. (PMID: 3464433)
      J Mol Med (Berl). 2015 Sep;93(9):991-1001. (PMID: 25869026)
      J Biol Chem. 1990 May 15;265(14):7880-5. (PMID: 2139874)
      Sheng Li Ke Xue Jin Zhan. 2009 Jan;40(1):24-30. (PMID: 19408699)
      ChemMedChem. 2017 Jan 5;12(1):42-49. (PMID: 27860402)
      Physiol Res. 2018 Oct 30;67(Suppl 2):S267-S279. (PMID: 30379549)
      Anticancer Drugs. 2022 Jan 1;33(1):e562-e572. (PMID: 34338241)
      BMC Cancer. 2021 Mar 25;21(1):321. (PMID: 33765976)
      Curr Med Chem. 2019;26(16):2933-2947. (PMID: 29376491)
      Biomed Rep. 2016 May;4(5):528-534. (PMID: 27123243)
      Transl Oncol. 2021 Aug;14(8):101140. (PMID: 34107419)
      Curr Opin Pharmacol. 2006 Oct;6(5):509-14. (PMID: 16860608)
      Cancer Res. 1987 Oct 15;47(20):5377-81. (PMID: 3115567)
      Cancer. 2000 Apr 15;88(8):1828-36. (PMID: 10760759)
      Asian Pac J Cancer Prev. 2016;17(4):1643-7. (PMID: 27221833)
      Peptides. 2021 Jul;141:170542. (PMID: 33794283)
      Curr Protein Pept Sci. 2017;19(2):211-220. (PMID: 28699510)
      Am J Transl Res. 2020 May 15;12(5):1754-1766. (PMID: 32509174)
      Int J Pharm. 2021 Jul 15;604:120710. (PMID: 34019972)
      Cancer Res. 1984 Dec;44(12 Pt 1):5914-20. (PMID: 6498849)
      Oncol Rep. 2002 Mar-Apr;9(2):267-76. (PMID: 11836591)
      Methods Mol Biol. 2021;2282:329-352. (PMID: 33928583)
      Drug Deliv. 2017 Nov;24(1):986-998. (PMID: 28644728)
      Adv Biomed Res. 2017 Mar 01;6:22. (PMID: 28349025)
      PLoS One. 2013 Jun 11;8(6):e66084. (PMID: 23776609)
      Gene Ther. 2017 Jan;24(1):40-48. (PMID: 27834948)
      J Natl Cancer Inst. 1987 Jan;78(1):55-60. (PMID: 3467130)
      Int J Oncol. 2016 Mar;48(3):1218-28. (PMID: 26780944)
    • الرقم المعرف:
      0 (Antineoplastic Agents)
      0 (Cell-Penetrating Peptides)
      0 (Gangliosides)
      0 (Single-Chain Antibodies)
      EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
    • الموضوع:
      Date Created: 20220601 Date Completed: 20220603 Latest Revision: 20220716
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC9159597
    • الرقم المعرف:
      10.1371/journal.pone.0269084
    • الرقم المعرف:
      35648774